Trinity Biotech PLC
IDA Business Park
Bray, Co
Wicklow
Tel: 353-1-276-9800-Or-800-603-8076
Fax: +353-1-276-9888
Website: http://www.trinitybiotech.com/
174 articles with Trinity Biotech PLC
-
Trinity Biotech plc to Announce First Quarter Fiscal Year 2022 Financial Results
6/29/2022
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2022 on Thursday, June 30, 2022.
-
Trinity Biotech Announces CE Mark of its 10-Minute Covid-19 Antigen Test
5/20/2022
Trinity Biotech plc (Nasdaq: TRIB) has achieved a CE Mark for its 10-minute Covid-19 antigen test.
-
Trinity Biotech Announces the Successful Closing of its Strategic Investment and Partnership With The MiCo Group of South Korea
5/3/2022
Trinity Biotech plc announced that it has closed its recently announced strategic investment with the MiCo Group.
-
Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.
-
Trinity Biotech Announces Quarter 4 and Fiscal Year 2021 Financial Results
4/11/2022
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced results for the quarter ended December 31, 2021 and fiscal year 2021.
-
Trinity Biotech Announces A $45 Million Strategic Investment And Partnership With The MiCo Group of South Korea
4/11/2022
Trinity Biotech plc today announced a $45 million strategic investment and partnership with MiCo Ltd (“MiCo”). MiCo, a KOSDAQ-listed and Korea-based company, is engaged in the biomedical business through its affiliate MiCo BioMed, in addition to providing cutting-edge technology driven solutions in the semi-conductor and green energy sectors.
-
Biopharma and life sciences companies from across the globe provide updates to their pipelines and businesses.
-
Trinity Biotech Announces the World Health Organisation Approval Of TrinScreen™ HIV
2/14/2022
Trinity Biotech plc (Nasdaq: TRIB) has received approval for its new HIV screening product, TrinScreen™ HIV, from the World Health Organisation (WHO).
-
Trinity Biotech Announces The Successful Closing of its Debt Refinancing
1/27/2022
Trinity Biotech plc today announced that it has closed its recently announced refinancing.
-
Trinity Biotech Announces Q3 2021 Results, the Entry Into a $81,250,000 Loan Facility to Refinance the Company’s Exchangeable Senior Notes and Agreements To Repurchase Outstanding Exchangeable Senior Notes
12/15/2021
Trinity Biotech plc announced results for the quarter ended September 30, 2021, the entry into a $81.25million loan facility to refinance the existing $99.9million of exchangeable senior notes issued by the Company’s subsidiary, Trinity Biotech Investment Limited, and exchange agreements for over 99.7% of the outstanding Notes, all subject to certain conditions precedent.
-
Trinity Biotech Announces Results for Q2, 2021
9/9/2021
Trinity Biotech plc today announced results for the quarter ended June 30, 2021.
-
Trinity Biotech Provides A Business Development Update For Q2 2021
7/16/2021
Trinity Biotech plc (Nasdaq: TRIB) provides a business development update for Q2 2021.
-
Trinity Biotech Announces Results for Q1, 2021
5/25/2021
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2021. Quarter 1 Results Total revenues for Q1, 2021 were $25.6m which compares to $21.2m in Q1, 2020, an increase of 20.9% and which were broken down as follows: 2020 Quarter 1 2021 Quarter 1 Increase/ (decrease)
-
Trinity Biotech plc to Announce First Quarter Fiscal Year 2021 Financial ResultsConference Call Scheduled for May 25, 2021 at 11:00 am EASTERN
5/19/2021
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2021 on Tuesday, May 25, 2021.
-
Trinity Biotech Announces Quarter 4 and Fiscal Year 2020 Financial Results
3/25/2021
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced results for the quarter ended December 31, 2020 and fiscal year 2020.
-
Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2020 Financial ResultsConference Call Scheduled for March 25, 2021 at 11:00 am EASTERN
3/23/2021
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2020 on Thursday, March 25, 2021.
-
Trinity Biotech Announces Results for Q3, 2020
11/17/2020
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2020. Quarter 3 Results Total revenues for Q3, 2020 were $32.0m, which is broken down as follows: 2019 Quarter 3 2020 Quarter 3 Change US$’000 US$’000 % Point-of-Care 3,880 2,065 (46.8)% Cl
-
Trinity Biotech plc to Announce Third Quarter 2020 Financial ResultsConference Call Scheduled for November 17, 2020 at 11:00 am EASTERN
10/29/2020
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter 2020 on Tuesday, November 17, 2020. The Company has scheduled a conference call for that same day, Tuesday, November 17, 2020 at 11:00am ET (4:00pm GMT) to discuss the results of the quarter. Interested parties can access the call by dialing: US Tol
-
Trinity Biotech Announces Results for Q2, 2020
8/25/2020
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2020.
-
Trinity Biotech announces EUA submission for Covid-19 ELISA Antibody test
8/20/2020
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets announced that it has filed its submission for an Emergency Use Authorization (EUA) for its Covid-19 IgG ELISA antibody test with the FDA. This test will determine which individuals within the population have been exposed to the SARS-CoV-2 virus. The transfer of production to our facility in Jame